Clinical study of CalliSpheres® microspheres drug-eluting bead-transarterial chemoembolization combined with sintilimab in the treatment of unresectable Hepatocellular carcinoma

This submission has open access
Submission ID :
GEST2021-31
Submission Type
Submission Topic
Sub-topics
IO
Purpose :
The present study evaluated the safety and efficacy of sintilimab (a programmed death-1 antibody) in combination with CalliSpheres® microspheres drug-eluting bead-transarterial chemoembolization (D-TACE) in unresectable Hepatocellular carcinoma.
Materials & Methods :
A total of 30 patients were prospectively enrolled.D-TACE was performed in On demand. Sintilimab was administered 5~7 days after D-TACE as a dose of 200 mg, which was repeated every 3 weeksuntil disease progression or intolerable toxicities. The primary endpoints were safety and the objective response rate (ORR). Other endpoints included progression-free survival (PFS) and overall survival (OS). Information about treatment response, survival and adverse events were collected.
Results :
The technical success rate was 100%. No treatment-associated deaths were identified.All patients reported treatment-related AEs (TRAEs). Grade 3-4 TRAEs were found in 4 (13.3%) patients. The ORR was 46.7% with two patients achieving complete response and 12 patients achieving partial response.As data cutoff of November 1, 2020, The median PFS was10.4 months and OS was not reached. The OS rates at 6 months and 12 months were 100.0 and 68.0%. No association was observed between TMB and efficacy.
Conclusions :
Sintilimab administration combined with D-TACE was safe in the treatment of unresectable Hepatocellular carcinoma , and the combination improved the ORR of Sintilimab alone compared to previous reports.

Associated Sessions

Attending physician
,
Shandong Cancer Hospital and Institute

Similar Abstracts by Type

Submission ID
Submission Title
Submission Topic
Submission Type
Primary Author
GEST2021-40
Ablation
Live - Oral Presentation
Shamar Young
GEST2021-85
Liver
Live - Oral Presentation
Mr. Courtney Henry
GEST2021-172
Live - Oral Presentation
Research Committee
GEST2021-173
Live - Oral Presentation
Research Committee
GEST2021-174
Live - Oral Presentation
Research Committee
GEST2021-175
Live - Oral Presentation
Research Committee
60 hits